Avadel Pharmaceuticals Responds to Unsolicited Proposal
Avadel Pharmaceuticals plc (NASDAQ: AVDL) has made waves with its recent reception of an unsolicited acquisition proposal from H. Lundbeck A/S. This offer could potentially fetch up to $23.00 per ordinary share, comprising significant cash and contingent payments based on performance metrics related to their products, LUMRYZ™ and valiloxybate. The Avadel board views this proposal as a potential "Company Superior Proposal" as it considers future valuations and the needs of its shareholders.
Details of the Lundbeck Proposal
The Lundbeck proposal aims to purchase Avadel for $23.00 per share, which includes $21.00 in cash at closing and a promising contingent value right (CVR) that will become significant based on the sales performance of LUMRYZ™ and valiloxybate. If these products reach sales milestones of $450 million and $700 million, respectively, additional payments of $1.00 per share will also be available to shareholders by the specified dates set for 2027 and 2030.
Existing Agreement with Alkermes
Before evaluating the Lundbeck proposal, Avadel had already entered into a transaction agreement with Alkermes plc (NASDAQ: ALKS) on October 22, 2025. Under this agreement, shareholders were set to receive $20.00 per ordinary share, inclusive of cash and a CVR contingent on FDA approval for LUMRYZ™. Despite the new proposal, Avadel's board acknowledges their commitment to the agreement with Alkermes while also allowing for discussions with Lundbeck amidst the ongoing negotiations.
Implications for Shareholders
Avadel's board is cautiously optimistic about the unsolicited proposal but has not officially declared it a superior offer yet, nor have they altered their recommendation regarding the Alkermes acquisition. With the need for shareholder and regulatory approval still looming, shareholders must remain attuned to ongoing discussions about the two competing proposals.
The Path Forward for Avadel
As conversations progress with Lundbeck, Avadel remains committed to ensuring transparency and diligence to uphold the value and trust of its shareholders. The future trajectory of Avadel depends not only on the conversations with Lundbeck but also on effective maneuvering within the current agreement with Alkermes. The dynamics at play symbolize a critical juncture in Avadel’s path as it navigates through these competing interests while striving for its long-term success.
Financial Advisory Support
To assist in these complex negotiations, Avadel has enlisted advisory support from Morgan Stanley and Goldman Sachs among others. Their expertise is vital as Avadel examines potential implications for its business strategy and shareholder value amid these discussions.
Frequently Asked Questions
What is the Lundbeck offer for Avadel?
The Lundbeck proposal values Avadel at up to $23.00 per ordinary share, which includes cash and contingent payments based on product sales.
How does this affect Avadel's agreement with Alkermes?
While the board is evaluating the new proposal, they have not changed their commitment to the existing agreement with Alkermes.
When are the milestones for the contingent value rights (CVR) in the Lundbeck proposal?
The milestones for the CVR are set for sales of LUMRYZ™ and valiloxybate to reach $450 million by 2027 and $700 million by 2030.
Who are the financial advisors supporting Avadel?
Morgan Stanley and Goldman Sachs are providing financial advice to help navigate the current acquisition discussions.
What is the current status of Avadel's negotiations with Lundbeck?
Discussions with Lundbeck are ongoing, but the board has not determined if it constitutes a superior proposal yet.
